title: Nelarabine activity in acute biphenotypic leukemia.
authors.forename: Yesid
authors.initials: Y
authors.lastname: Alvarado
authors.forename: Mary Alma
authors.initials: MA
authors.lastname: Welch
authors.forename: Ronan
authors.initials: R
authors.lastname: Swords
authors.forename: John
authors.initials: J
authors.lastname: Bruzzi
authors.forename: Ellen
authors.initials: E
authors.lastname: Schlette
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
mesh_terms: D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001087:Arabinonucleosides / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005434:Flow Cytometry; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D010641:Phenotype; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D014750:Vincristine; C104457:nelarabine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide